Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Fecha de publicación
2014Título de revista
AMERICAN JOURNAL OF HEMATOLOGY
Tipo de contenido
Artigo
![](/xmlui/themes/Mirage2//images/final_lines.png)